Generic Threat To Amarin's Vascepa Overrides Positive Sentiment On Coronavirus Announcement
Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment
The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions
Amarin Shares Drop 67% As Court Invalidates Its Heart Drug Patent For Vascepa
Vascepa Recent News
PreMarket Prep Stock Of The Day: Amarin
After Amarin Snags Vascepa Label Expansion, Analyst Says Biopharma An Attractive M&A Target
Analyst: Peak Sales Potential Of Amarin's Vascepa Underappreciated
Amarin's Vascepa Adcom Meeting: What You Need To Know
Amarin Shares Climb Following In-Line Review Of Fish Oil Pill By FDA Staffers
Amarin Shares Topple On Adcom Meeting Surprise For Fish Oil Pill
Amarin's Cardiovascular Fish Oil Pill May Hit Market Sooner: FDA Accords Priority Review Designation
Amarin Rallies After Diabetes Association Adds Fish Oil Capsule To Standards of Care List
Amarin Reports Encouraging Data, Vascepa Shows 30% Reduction In Total Cardiovascular Events In REDUCE-IT Study
Amarin Trades Down After Release Of Late-Stage Vascepa Trial Results
Analyst: Amarin's Vascepa Results Create Unicorn Potential, M&A Opportunity
Amarin Shares Skyrocket On Positive Cardio Trial Results
Amarin Soars After Vascepa Settlement
EXCLUSIVE: Expect Amarin FAQ Shortly
Amarin's Vascepa: Too Limited A Market Or FDA Blunder?
Trading in Amarin Muted After Thursday's After Hours Massacre